BCLC Stage C Hepatocellular Carcinoma Clinical Trials

18 clinical trials for BCLC Stage C Hepatocellular Carcinoma across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma — RECRUITING · PHASE2
• Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC — RECRUITING · PHASE3
• Liver Cancer and Immunotherapy in the Liquid Biopsy Era — RECRUITING · NA
• HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC — RECRUITING
• A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab — TERMINATED · PHASE2
• Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients — ACTIVE_NOT_RECRUITING · NA
• HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) — COMPLETED
• Using Machine Learning to Identify Responders to TACE or HAIC for uHCC — COMPLETED
• Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer — COMPLETED · PHASE2
• Pembrolizumab (MK-3475) in Hepatocellular Carcinoma — COMPLETED · PHASE2
• BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy — COMPLETED · PHASE1
• Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer — TERMINATED · PHASE2
• BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer — TERMINATED · PHASE1
• TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC — OTHER · PHASE2
• Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma — WITHDRAWN · PHASE2
• Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery — COMPLETED · PHASE2
• The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer — OTHER · PHASE2

Refine this search